Vitravene Injection
Company: Isis Pharmaceuticals
Approval Status: Approved August 1998
Treatment for: CMV Retinitis
Areas: Ophthalmology
| General Information | Clinical Results | Side Effects |
General Information
Vitravene Injection for the local treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are intolerant of or have a contraindication to other treatment(s) for CMV retinitis or who were insufficiently responsive to previous treatment(s) for CMV retinitis.
The use of Vitravene does not provide treatment for systemic CMV disease.
Clinical Results
Vitravene injection is not a cure for CMV retinitis, and some immunocompromised patients may continue to experience progression of retinitis during and following treatment. Patients receiving Vitravene should be advised to have regular ophthalmologic follow-up examinations. Patients may also experience other manifestations of CMV disease despite Vitravene therapy.
Side Effects
Abdomianl pain, anemia, diarrhea, fever, headache, infection, nausea, pneumonia, rash, etc.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
